Clinical Operations & Strategy

Latest News


Latest Videos


Shorts

Translational Medicine's Growing Role in IBD Research
0:47
Translational Medicine's Growing Role in IBD Research
3 months ago
by
Kori Wallace, MD, PhD(+2 more)
The New Era of Drug Development: Speed Over Science?
0:54
The New Era of Drug Development: Speed Over Science?
4 months ago
by
Stella K. Vnook, PhD(+1 more)
Why Execution is Never Just 'Plug and Play'
0:42
Why Execution is Never Just 'Plug and Play'
4 months ago
by
Elizabeth Walsh, PMP, ACRP-CP(+1 more)
ACT Ops Take: Improving Clinical Development Productivity
1:45
ACT Ops Take: Improving Clinical Development Productivity
6 months ago
by
Andy Studna, Senior Editor
Why I Chose Clinical Trials: A Statistician's Story
0:40
Why I Chose Clinical Trials: A Statistician's Story
6 months ago
by
Sam Hinsley(+1 more)
Why the Shift to Patient-Centric Clinical Trials is Crucial
0:45
Why the Shift to Patient-Centric Clinical Trials is Crucial
9 months ago
by
Miriam Dervan
ESG is No Longer Optional: It's a Readiness Test
0:35
ESG is No Longer Optional: It's a Readiness Test
9 months ago
by
Otis Johnson, PhD, MPA(+1 more)
The Hidden Cost of Efficiency in Clinical Trials
0:58
The Hidden Cost of Efficiency in Clinical Trials
10 months ago
by
Liz Beatty(+1 more)
Why Marketers Use Reddit vs. TikTok for Healthcare Audiences
0:32
Why Marketers Use Reddit vs. TikTok for Healthcare Audiences
a year ago
by
Christian Bullock(+1 more)
Why Safety Risk Should Be as Important as Efficacy in Trials
0:30
Why Safety Risk Should Be as Important as Efficacy in Trials
a year ago
by
Ananth Kadambi(+1 more)

More News

In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.

© putilov_denis - © putilov_denis - stock.adobe.com

Cell and gene therapy access expands into community care settings only when operational coordination, site readiness, and supply chain standardization become first-order priorities equivalent to manufacturing capacity, requiring standardized processes, digital integration, and distributed logistics networks.

In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, about why defensible trial data depends on traceability, platform ownership, and device strategy long after a study ends.

This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.

This pilot episode of The Human Side of Clinical Trials introduces a framework from Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., exploring why operational failures in clinical trials often trace back to gaps in human readiness rather than process design alone.

In this Q&A, Stella K. Vnook, PhD, CEO and executive chair of Kaida BioPharma and founder and CEO of Aviva Ventures, discusses how a trifecta of funding pressures is reshaping early-stage clinical development, why commercialization readiness can no longer wait until late-stage, and what a truly strategic lean development model looks like in practice.